Benign Prostatic Hyperplasia Treatment Market Size, Demand, Competitive Analysis, Regional Growth and Forecast by 2026

According to IMARC Group's latest report, titled "Benign Prostatic Hyperplasia Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026", the global benign prostatic hyperplasia treatment market reached a value of US$ 10.5 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 5.6% during 2021-2026.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Request a Free PDF Sample of the Report: https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market/requestsample

Benign prostatic hyperplasia (BPH) refers to non-cancerous growth of the prostate gland that causes urethra blockage. This disorder generally results in the retention of urine, formation of bladder stones, incontinence due to overfilling, increased sensitivity of the bladder, and urinary tract infections. Some commonly used treatment methods for BPH include prescription drugs, mono drug and combination therapy, Phyto-therapies, and minimally-invasive (MI) and invasive surgeries. Resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants are some of the standard instruments used in BPH treatment surgeries.

Market Trends and Drivers:

The rising prevalence of urological disorders across the globe, coupled with the growing geriatric population, is currently driving the benign prostatic hyperplasia treatment market growth. Furthermore, the increasing consumer awareness towards the availability of efficient and minimally-invasive treatment procedures for BPH is also propelling the market. Moreover, various advancements in the medical sector have led to the development of transurethral resection of the prostate (TURP) as an efficient treatment technique. TURP is an endoscopic electrosurgical procedure that removes a portion of the prostate gland to reduce the obstruction caused by abnormal growth. In addition to this, the rising healthcare expenditures and improving healthcare infrastructures will continue to drive the market growth in the coming years.

Benign Prostatic Hyperplasia Treatment Market 2021-2026 Competitive Analysis and Segmentation:

Competitive Landscape With Key Players:

The competitive landscape of the benign prostatic hyperplasia treatment market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

Abbott Laboratories
GlaxoSmithKline Plc
Boston Scientific Corporation
Pfizer Inc.
Asahi Kasei Corporation
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Allergan Plc (AbbVie Inc.)
Astellas Pharma Inc.
Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)

Key Market Segmentation:

The report has segmented the global benign prostatic hyperplasia treatment market on the basis of treatment and region.

Market Breakup by Treatment:

Drug Class
Alpha-Blockers
5-Alpha-reductase Inhibitors (5-ARIs)
Phosphodiesterase-5 Enzyme Inhibitors
Others
Minimally Invasive Surgeries
Transurethral Resection of the Prostate (TURP)
Transurethral Incision of the Prostate (TUIP)
Transurethral Microwave Thermotherapy (TUMT)
Robotic Surgeries
Prostatic Urethral Lifts
Others
Laser Therapy
Others

Market Breakup by Region:

North America
Asia Pacific
Europe
Latin America
Middle East and Africa

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=2898&flag=C
Key Highlights of the Report:

Market Performance (2015-2020)
Market Outlook (2021-2026)
Market Trends
Market Drivers and Success Factors
Impact of COVID-19
Value Chain Analysis
Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

This release was published on openPR.